Although certain cancers, such as sarcomas and uterine cancer, have amplifications in PARK2 gene, the majority of tumors with lesions in PARK2, including ovarian, breast, and lung cancers, harbor deletions or loss of function mutations. This evidence concerns the gene PRKN and lung cancer.